Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABT-712 (Vicodin CR) is an extended-release, fixed-dose combination oral tablet developed by Abbott Laboratories (now AbbVie). It contains hydrocodone bitartrate, a mu-opioid receptor agonist, and acetaminophen, a non-opioid analgesic and antipyretic that acts as a cyclooxygenase inhibitor. The formulation was designed to provide sustained pain relief for acute and chronic conditions, including post-surgical pain (e.g., dental extraction, bunionectomy) and chronic low back pain or osteoarthritis. Clinical development reached Phase 3, but the product was ultimately discontinued and did not receive regulatory approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocodone + acetaminophen.